ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,651.00
11.50 (0.70%)
23 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  11.50 0.70% 1,651.00 1,651.00 1,652.00 1,656.00 1,637.00 1,650.50 4,661,376 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.80 68.01B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,639.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £68.01 billion. Gsk has a price to earnings ratio (PE ratio) of 13.80.

Gsk Share Discussion Threads

Showing 19126 to 19148 of 33100 messages
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
DateSubjectAuthorDiscuss
07/2/2019
07:09
Don't know this posted twice, repetition deleted
hydrogen economy
07/2/2019
07:09
Broadgreen

As you say Div was very well covered by FCF in 2018 (indeed Q418 FCF at 3.3b almost covered the FY divis),but it was distorted by one offs :-

-Reduction of inventory balances
-favourable timing of payments for returns and rebates
-reduced legal settlement costs and restructuring payments,
-lower capital expenditure
-increased disposals of intangible assets of £256 million

But
Profits expected to drop again next year and one-offs could well go the other way.

The number of deals being done means lots of one-off costs so I think no certainty of a rise in 2020, we can only watch and hope.

hydrogen economy
07/2/2019
03:39
Glaxo hunts more deals to stay competitive, Walmsley says



GlaxoSmithKline strategy revamp and shingles drug help boost earnings

xxxxxy
06/2/2019
17:31
Net debt has increased from 13bn to 21bn.

We better start generating bigger profits.

zicopele
06/2/2019
16:55
Can’t see why any of us is not delighted at the share price movement over the last two days, except anhar, of course, to whom it does not matter!
jadeticl3
06/2/2019
16:40
You must have said the same thing now over ten times in January..why?
badtime
06/2/2019
16:10
Emma Walmsley, CEO, GSK, summarises our performance in 2018
wbecki
06/2/2019
16:08
Looks like another test of 1600 on the cards.
tim 3
06/2/2019
15:43
Don't worry about it,such concerns are discounted in the current rating.
steeplejack
06/2/2019
15:38
No higher dividends any time soon.

Major investment in drug discovery required and debts which are extremely high.

zicopele
06/2/2019
15:32
I'm a bit puzzled by the following - maybe someone better at deciphering financial statements can shed some light:

2018 dividends cost £3935m

Aim is to build Free Cash Flow/Dividend cover to 1.25x - 1.5x before raising the dividend. That implies FCF of £4918m-£5902m before divi can be increased.

But 2018 FCF was £5692m. Almost at the top of the targeted cover range. Does this imply higher dividends soon, despite the forecast unchanged 80p dividend for 2019?

broadgreen
06/2/2019
15:22
GlaxoSmithKline gaining 0.3 percent to 1.527 pence after the British pharmaceutical laboratory announced Wednesday that its pre-tax profit had more than tripled in the fourth quarter.
The Group also indicated that generic products of its competitors might does not affect its results of 2019 as much as some anticipated it. Jefferies, the market should appreciate the goal of the group to a drop of 5% to 9% of earnings per share at constant exchange rates this year, as many feared a double-digit decline."Current consensus lies just below the middle of the range for earnings per share, which indicates that it should evolve in a limited way", noted analysts at Jefferies

beckers2008
06/2/2019
15:19
You're made off strong stuff Monty, even my cats won't go out today.


Phil, that might be a good short term move.

essentialinvestor
06/2/2019
15:10
Just back from golf, superb, 1635p here we come.
montyhedge
06/2/2019
14:48
Stock has broken through $40 in the USA,highest level in a couple of months.The USA will ultimately dictate how the stock moves.
steeplejack
06/2/2019
14:39
A quick scan of the balance sheet has two big movements - the derecognition of non-controlling interests and borrowings. Linked to the JV.
alphorn
06/2/2019
13:46
Yes, Merrill Lynch have upgraded VOD to 'buy' this morning. They reckon a one-third cut in the dividend is now priced in.

Top sliced 10% off GSK a few minutes ago.

philanderer
06/2/2019
13:37
Slowly but surely a lot of the apparent high yielders are being wormed out.Jeffries thinks Vodaphone will have to cut the dividend in due course,now on a historic yield of over 9%.Thus,Glaxo forecasting a maintained dividend for 2019 puts it in the safe yield camp prospectively yielding over 5%.Makes Glaxo a very sound investment in 2019 (despite the dip in earnings this year)if you care to look longer term.
steeplejack
06/2/2019
13:15
Buy these pesky dips and pull backs Sir!
ny boy
06/2/2019
13:13
Who sold before the results ?
abdullla
06/2/2019
12:59
Yes, Anhar, as if that was the main representative news! (and its hardly 'news' - this has been heralded for over 2 years)
tradermichael
06/2/2019
12:45
Computer generated nonsense probably tm
nimbo1
06/2/2019
12:44
Yes , that was a quick buy from a non-exec director :-)

2,926.421 @ 14.95p

philanderer
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older

Your Recent History

Delayed Upgrade Clock